Intelgenx Technologs (IGXT) 0.6750 $IGXT
IntelGenx Founder, President and CEO Dr. Horst Zerbe Interviewed on Fox Business Network's "After the Bell"
GlobeNewswire - Fri Apr 10, 7:46AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx"
today announced its President and CEO Dr. Horst G. Zerbe, was a guest on FOX Business Network's After the Bell (weekdays 4-5PM/ET) on Thursday, April 9, 2015.
IGX.VN: 0.980 (+0.210)
IntelGenx Grants Stock Options
GlobeNewswire - Thu Apr 02, 11:14AM CDT
IntelGenx Technologies Corp. ("IntelGenx", or the "Company" (TSX-V:IGX) (OTCQX:IGXT) announced today that the Company's board of directors granted options to acquire a total of 300,000 common shares under the 2006 Stock Option Plan, as amended.
IGX.VN: 0.980 (+0.210)
IntelGenx Technologies' (IGXT) CEO Horst Zerbe on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 01, 3:27PM CDT
IntelGenx Reports 2014 Annual Results and Provides Corporate Development Update
ACCESSWIRE - Tue Mar 31, 7:14AM CDT
SAINT LAURENT, QUEBEC / ACCESSWIRE / March 31, 2015 / IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx" today announced financial results for its fiscal year ended December 31, 2014 and provided an update on operational developments. All amounts are in U.S. Dollars, unless otherwise stated.
IGX.VN: 0.980 (+0.210)
IntelGenx to Report 2014 Annual Results and Provide Corporate Development Update on March 31, 2015
GlobeNewswire - Mon Mar 23, 7:02AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx", or the "Company" a leading drug delivery company focused on the development of novel rapidly disintegrating delivery systems as well as oral controlled-release products, today announced that it will release its 2014 annual results for the period and full year ended December 31, 2014, on March 31, 2015 at the open of the financial markets.
IGX.VN: 0.980 (+0.210)
Global Migraine Drugs Market 2015-2019 with Abbott, Allergan, Eisai, Endo, GlaxoSmithKline, Impax Laboratories & Pfizer Dominating
M2 - Fri Feb 06, 8:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/s55lbq/global_migraine) has announced the addition of the "Global Migraine Drugs Market 2015-2019" report to their offering. The Global Migraine Drugs market to grow at a CAGR of 3.54% over the period 2014-2019. Migraine is a complex neurological medicial condition characterized by a severe headache. The headache is often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Given their hormonal fluctuation, women are more susceptible to have migraine than men. Anti-migraine drugs are the therapeutic agents to be used against migraine. Treatment includes painkillers, anti-inflammatory painkillers, anti-sickness medicines, and triptan medicines. The development of new drugs such as CGRP receptor antagonist and Botox is one of the major trends emerging in the market. Moreover, the demand for anti-migraine drugs is expected to grow further driving the market growth. According to the report, an increased prevalence of migraine is one of the main drivers of the market. Migraine is highly prevalent worldwide and affects people irrespective of their age, race, level of income, and geographical location. Further, the report states that the high cost of drugs is one of the main challenges faced by the market. Regardless of the numerous benefits, the high cost of drugs impedes acceptability among patients. The manufacturing process of a generic involves the use of the right equipment, expertise, and the ability to demonstrate to the FDA that the generic is absorbed through the skin in quantities that are identical to that of the branded drug. This cycle leads to an increase in the manufacturing costs, thereby increasing the overall cost of the drug. Key Vendors - Abbott - Allergan - Eisai - Endo - GlaxoSmithKline - Impax Laboratories - Pfizer Other Prominent Vendors - Almirall - Amgen - AstraZeneca - Boehringer Ingelheim - Eli Lilly - IntelGenx Technologies - Johnson & Johnson - Nautilus - OptiNose - RedHill Biopharma - Zogenix Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Migraine Pipeline Snapshot - Migraine Pipeline Assessment - Market Segmentation by Therapeutic Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/s5...l_migraine
IPXL: 50.68 (-0.43), AGN: 240.22 (+2.88), JNJ: 102.06 (+0.73), RDHL: 14.34 (+0.19), AMGN: 163.38 (+1.89), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51)
IntelGenx to Present at the 8th Annual OneMedForum
GlobeNewswire - Mon Jan 05, 7:25AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the 8 Annual OneMedForum to be held Monday, January 12, 2015 at the San Francisco Marriott Marquis. IntelGenx' presentation will take place January 12, 2015 at 10:40 A.M. Pacific Time.
IGX.VN: 0.980 (+0.210)
IntelGenx Grants Extension of Marketing Exclusivity in the U.S. to Edgemont of Forfivo XL(R)
GlobeNewswire - Tue Dec 02, 6:32AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that its licensing partner Edgemont Pharmaceuticals, LLC ("Edgemont" has exercised its right to extend the license for the exclusive marketing of Forfivo XL(R) 450 mg tablets.
IGX.VN: 0.980 (+0.210)
German regulator starts review of Rizaport MAA
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 7:43AM CST
RDHL: 14.34 (+0.19)
IntelGenx and RedHill Biopharma Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
GlobeNewswire - Mon Dec 01, 7:03AM CST
-- The German Federal Institute for Drugs and Medical Devices ("BfArM" has validated the European Marketing Authorization Application submitted for RIZAPORT(TM) and initiated its formal review of the application on November 25, 2014
RDHL: 14.34 (+0.19), IGX.VN: 0.980 (+0.210)
RedHill Biopharma and IntelGenx Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
GlobeNewswire - Mon Dec 01, 7:00AM CST
-- The German Federal Institute for Drugs and Medical Devices (BfArM) has validated the European Marketing Authorization Application submitted for RIZAPORT (RHB-103) and initiated its formal review of the application on November 25, 2014
RDHL: 14.34 (+0.19), IGX.VN: 0.980 (+0.210)
IntelGenx Announces Update to Settlement of U.S. Patent Litigation Related to Forfivo XL(R)
GlobeNewswire - Wed Nov 26, 7:41AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that it has settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx' Forfivo XL(R) 450 mg tablets.
IGX.VN: 0.980 (+0.210)
IntelGenx Announces Settlement of U.S. Patent Litigation Related to Forfivo XL(R)
GlobeNewswire - Tue Nov 25, 7:08AM CST
IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that it has settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx' Forfivo XL(R) 450 mg tablets.
IGX.VN: 0.980 (+0.210)
Stocks to watch ahead of the "Best of the Uncovereds" conference
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 6:45AM CST
ACET: 21.56 (-0.06), ACU: 18.71 (-0.09), MNTX: 8.79 (-0.33), TREC: 12.25 (+0.10), INTL: 31.01 (+0.25), HPJ: 4.29 (-0.14), SPA: 26.05 (+0.01), AXPW: 0.04 (+0.01), DXPE: 45.21 (-0.04), LODE: 0.68 (+0.01), LABL: 64.41 (-3.69), NEWT: 17.72 (+0.04), SA: 6.60 (+0.30), PSEC: 8.39 (unch)
IntelGenx to Present at Singular Research's Best of the Uncovered 2014 NYC Fall Conference
GlobeNewswire - Tue Nov 18, 7:40AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the Singular Research Best of the Uncovered 2014 NYC Fall Conference to be held Thursday, November 20, 2014 at the Westin in New York at Times Square. IntelGenx' presentation will take place November 20, 2014 at 12:00 PM Eastern Time.
IGX.VN: 0.980 (+0.210)
IntelGenx Founder, President and CEO Dr. Horst Zerbe Interviewed on Fox Business Network's "After the Bell"
GlobeNewswire - Fri Apr 10, 7:46AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx"
today announced its President and CEO Dr. Horst G. Zerbe, was a guest on FOX Business Network's After the Bell (weekdays 4-5PM/ET) on Thursday, April 9, 2015. IGX.VN: 0.980 (+0.210)
IntelGenx Grants Stock Options
GlobeNewswire - Thu Apr 02, 11:14AM CDT
IntelGenx Technologies Corp. ("IntelGenx", or the "Company"
(TSX-V:IGX) (OTCQX:IGXT) announced today that the Company's board of directors granted options to acquire a total of 300,000 common shares under the 2006 Stock Option Plan, as amended. IGX.VN: 0.980 (+0.210)
IntelGenx Technologies' (IGXT) CEO Horst Zerbe on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 01, 3:27PM CDT
IntelGenx Reports 2014 Annual Results and Provides Corporate Development Update
ACCESSWIRE - Tue Mar 31, 7:14AM CDT
SAINT LAURENT, QUEBEC / ACCESSWIRE / March 31, 2015 / IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx"
today announced financial results for its fiscal year ended December 31, 2014 and provided an update on operational developments. All amounts are in U.S. Dollars, unless otherwise stated. IGX.VN: 0.980 (+0.210)
IntelGenx to Report 2014 Annual Results and Provide Corporate Development Update on March 31, 2015
GlobeNewswire - Mon Mar 23, 7:02AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx", or the "Company"
a leading drug delivery company focused on the development of novel rapidly disintegrating delivery systems as well as oral controlled-release products, today announced that it will release its 2014 annual results for the period and full year ended December 31, 2014, on March 31, 2015 at the open of the financial markets. IGX.VN: 0.980 (+0.210)
Global Migraine Drugs Market 2015-2019 with Abbott, Allergan, Eisai, Endo, GlaxoSmithKline, Impax Laboratories & Pfizer Dominating
M2 - Fri Feb 06, 8:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/s55lbq/global_migraine) has announced the addition of the "Global Migraine Drugs Market 2015-2019" report to their offering. The Global Migraine Drugs market to grow at a CAGR of 3.54% over the period 2014-2019. Migraine is a complex neurological medicial condition characterized by a severe headache. The headache is often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Given their hormonal fluctuation, women are more susceptible to have migraine than men. Anti-migraine drugs are the therapeutic agents to be used against migraine. Treatment includes painkillers, anti-inflammatory painkillers, anti-sickness medicines, and triptan medicines. The development of new drugs such as CGRP receptor antagonist and Botox is one of the major trends emerging in the market. Moreover, the demand for anti-migraine drugs is expected to grow further driving the market growth. According to the report, an increased prevalence of migraine is one of the main drivers of the market. Migraine is highly prevalent worldwide and affects people irrespective of their age, race, level of income, and geographical location. Further, the report states that the high cost of drugs is one of the main challenges faced by the market. Regardless of the numerous benefits, the high cost of drugs impedes acceptability among patients. The manufacturing process of a generic involves the use of the right equipment, expertise, and the ability to demonstrate to the FDA that the generic is absorbed through the skin in quantities that are identical to that of the branded drug. This cycle leads to an increase in the manufacturing costs, thereby increasing the overall cost of the drug. Key Vendors - Abbott - Allergan - Eisai - Endo - GlaxoSmithKline - Impax Laboratories - Pfizer Other Prominent Vendors - Almirall - Amgen - AstraZeneca - Boehringer Ingelheim - Eli Lilly - IntelGenx Technologies - Johnson & Johnson - Nautilus - OptiNose - RedHill Biopharma - Zogenix Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Migraine Pipeline Snapshot - Migraine Pipeline Assessment - Market Segmentation by Therapeutic Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/s5...l_migraine
IPXL: 50.68 (-0.43), AGN: 240.22 (+2.88), JNJ: 102.06 (+0.73), RDHL: 14.34 (+0.19), AMGN: 163.38 (+1.89), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51)
IntelGenx to Present at the 8th Annual OneMedForum
GlobeNewswire - Mon Jan 05, 7:25AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"
today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the 8 Annual OneMedForum to be held Monday, January 12, 2015 at the San Francisco Marriott Marquis. IntelGenx' presentation will take place January 12, 2015 at 10:40 A.M. Pacific Time. IGX.VN: 0.980 (+0.210)
IntelGenx Grants Extension of Marketing Exclusivity in the U.S. to Edgemont of Forfivo XL(R)
GlobeNewswire - Tue Dec 02, 6:32AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"
today announced that its licensing partner Edgemont Pharmaceuticals, LLC ("Edgemont" has exercised its right to extend the license for the exclusive marketing of Forfivo XL(R) 450 mg tablets. IGX.VN: 0.980 (+0.210)
German regulator starts review of Rizaport MAA
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 7:43AM CST
RDHL: 14.34 (+0.19)
IntelGenx and RedHill Biopharma Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
GlobeNewswire - Mon Dec 01, 7:03AM CST
-- The German Federal Institute for Drugs and Medical Devices ("BfArM"
has validated the European Marketing Authorization Application submitted for RIZAPORT(TM) and initiated its formal review of the application on November 25, 2014 RDHL: 14.34 (+0.19), IGX.VN: 0.980 (+0.210)
RedHill Biopharma and IntelGenx Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
GlobeNewswire - Mon Dec 01, 7:00AM CST
-- The German Federal Institute for Drugs and Medical Devices (BfArM) has validated the European Marketing Authorization Application submitted for RIZAPORT (RHB-103) and initiated its formal review of the application on November 25, 2014
RDHL: 14.34 (+0.19), IGX.VN: 0.980 (+0.210)
IntelGenx Announces Update to Settlement of U.S. Patent Litigation Related to Forfivo XL(R)
GlobeNewswire - Wed Nov 26, 7:41AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"
today announced that it has settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx' Forfivo XL(R) 450 mg tablets. IGX.VN: 0.980 (+0.210)
IntelGenx Announces Settlement of U.S. Patent Litigation Related to Forfivo XL(R)
GlobeNewswire - Tue Nov 25, 7:08AM CST
IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx"
today announced that it has settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx' Forfivo XL(R) 450 mg tablets. IGX.VN: 0.980 (+0.210)
Stocks to watch ahead of the "Best of the Uncovereds" conference
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 6:45AM CST
ACET: 21.56 (-0.06), ACU: 18.71 (-0.09), MNTX: 8.79 (-0.33), TREC: 12.25 (+0.10), INTL: 31.01 (+0.25), HPJ: 4.29 (-0.14), SPA: 26.05 (+0.01), AXPW: 0.04 (+0.01), DXPE: 45.21 (-0.04), LODE: 0.68 (+0.01), LABL: 64.41 (-3.69), NEWT: 17.72 (+0.04), SA: 6.60 (+0.30), PSEC: 8.39 (unch)
IntelGenx to Present at Singular Research's Best of the Uncovered 2014 NYC Fall Conference
GlobeNewswire - Tue Nov 18, 7:40AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"
today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the Singular Research Best of the Uncovered 2014 NYC Fall Conference to be held Thursday, November 20, 2014 at the Westin in New York at Times Square. IntelGenx' presentation will take place November 20, 2014 at 12:00 PM Eastern Time. IGX.VN: 0.980 (+0.210)
